Flagship spinout Axcella collapses, leaving future of its long Covid drug uncertain

A Flagship Pioneering-backed biotech behind one of the only new drugs in development for long Covid is closing its doors.

Previous Boston-based Leerink Partners opens Miami office
Next HealthStream expands services to nursing schools, students to increase revenue